Joel Greenblatt's CPRX Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 61,371 shares of Catalyst Pharmaceuticals, Inc. (CPRX) worth $1.52 M, representing 0.00% of the portfolio. First purchased in 2019-Q3, this long-term strategic position has been held for 21 quarters.
Based on 13F filings, Joel Greenblatt has maintained a strategic position in CPRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2023, adding 120,406 shares. Largest reduction occurred in Q4 2025, reducing 79,378 shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Catalyst Pharmaceuticals (CPRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Catalyst Pharmaceuticals (CPRX) Trades by Joel Greenblatt
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -594 | Reduce 0.96% | 61,371 | $24.76 |
| Q4 2025 | -79,378 | Reduce 56.16% | 61,965 | $23.34 |
| Q3 2025 | +31,618 | Add 28.82% | 141,343 | $19.70 |
| Q2 2025 | +62,416 | Add 131.93% | 109,725 | $21.70 |
| Q1 2025 | +8,356 | Add 21.45% | 47,309 | $24.25 |
| Q4 2024 | +2,812 | Add 7.78% | 38,953 | $20.87 |
| Q3 2024 | +2,444 | Add 7.25% | 36,141 | $19.88 |
| Q2 2024 | -1,491 | Reduce 4.24% | 33,697 | $15.49 |
| Q1 2024 | -2,314 | Reduce 6.17% | 35,188 | $15.94 |
| Q4 2023 | -76,504 | Reduce 67.11% | 37,502 | $16.81 |
| Q3 2023 | +3,532 | Add 3.20% | 114,006 | $11.69 |
| Q2 2023 | -28,977 | Reduce 20.78% | 110,474 | $13.44 |
| Q1 2023 | +120,406 | Add 632.22% | 139,451 | $16.58 |
| Q4 2022 | -31,130 | Reduce 62.04% | 19,045 | $18.60 |
| Q3 2022 | +50,175 | New Buy | 50,175 | $12.84 |
| Q4 2020 | -32,653 | Sold Out | 0 | $0.00 |
| Q3 2020 | -37,219 | Reduce 53.27% | 32,653 | $2.97 |
| Q2 2020 | -57,062 | Reduce 44.95% | 69,872 | $4.62 |
| Q1 2020 | +90,420 | Add 247.63% | 126,934 | $3.85 |
| Q4 2019 | -3,306 | Reduce 8.30% | 36,514 | $3.75 |
| Q3 2019 | +39,820 | New Buy | 39,820 | $5.30 |
Joel Greenblatt's Catalyst Pharmaceuticals Investment FAQs
Joel Greenblatt first purchased Catalyst Pharmaceuticals, Inc. (CPRX) in Q3 2019, acquiring 39,820 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Catalyst Pharmaceuticals, Inc. (CPRX) for 21 quarters since Q3 2019.
Joel Greenblatt's largest addition to Catalyst Pharmaceuticals, Inc. (CPRX) was in Q1 2023, adding 139,451 shares worth $2.31 M.
According to the latest 13F filing for Q1 2026, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 61,371 shares of Catalyst Pharmaceuticals, Inc. (CPRX), valued at approximately $1.52 M.
As of the Q1 2026 filing, Catalyst Pharmaceuticals, Inc. (CPRX) represents approximately 0.00% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings.
Joel Greenblatt's peak holding in Catalyst Pharmaceuticals, Inc. (CPRX) was 141,343 shares, as reported at the end of Q3 2025.